Tag: Petrovax

NPO Petrovax Pharm is the leader among Russian companies engaged in research, development and production of innovative medicines and vaccines.
Founded in 1996 by a group of Russian scientists, the company aims to create, produce and promote original medicines across the national health care system.
Petrovax Pharm’s pharmaceutical production and warehousing complex (Podolsk District, Moscow Region) was opened in 2008 and is now one of the most advanced high-tech biopharmaceutical facilities in Russia.
It manufactures substances and liquid, semi-solid and solid dosage forms in disposable syringes, ampoules, vials and plastic containers. The production capacity is over 160 m doses of immunobiological medicines per year.
The facility includes a production and warehousing block, laboratories, a power block, a water treatment block, and an office and amenities building.
The complex currently comprises two production lines manufacturing Grippol® Plus and Prevenar® 13 vaccines in pre-filled syringes, along with Polyoxidonium® and Longidaze® in ampoules and vials. Construction of the third production line for substances, solid and semi-solid formulations is now in progress and is due to come on-stream in 2017. As the next step, the company plans to ramp up its production capacity to a total of four lines, expand its warehouse space, and add another office building.

Product Quality team currently has more than 80 professionals working to ensure impeccable quality for NPO Petrovax Pharm medicines across all production stages – from taking samples of starting materials to end product quality check. The production is fully compliant with the Russian and international GMP and ISO:9001 standards. The company is the only producer of immunobiological medicines in Russia holding GMP certificates issued by government regulators from the EU (Slovakia), Ukraine and Iran. The company operates its own warehouse to ensure proper storage of produced pharmaceuticals.
Petrovax Pharm has a set of well-established pre-production practices in place both for its vaccines and other medicines. It also carries out annual engineering audits and a full set of certification and validation procedures (certification of engineering systems and clean rooms, validation of aseptic filling and water treatment systems, preparation and packaging processes).

The production of a quadrivalent influenza vaccine was launched in Podolsk

The vaccine was registered in 2018 and became Russia's first quadrivalent influenza vaccine - it protects against two influenza A virus infection (H1N1 and H3N2) and two influenza B virus infection.

Russia will have its first quadrivalent influenza vaccine

According to the experts, this vaccine has not only the most effective and safe profile possible today, but also provides undeniable pharmacoeconomic advantages.

First lots of Actilyse® localized in Russia arrive to medical facilities

Boehringer Ingelheim and NPO Petrovax Pharm have successfully completed another stage of their work to localize the manufacturing of innovative thrombolytics in the Russian Federation.

Russian pharma companies are registering medicines in more than 60 countries

When Pharma-2020 was launched in 2010, its first priority was to provide domestically manufactured medicines

Quality Management System of Petrovax meets the requirements of ISO 9001:2015

In October, NPO Petrovax Pharm confirmed the compliance of its Quality Management System (QMS) with the requirements of ISO 9001:2015

Petrovax completed the first stage of thrombolitics production localization

Boehringer Ingelheim and Petrovax Pharm have successfully completed the first major stage of their work to transfer the technology for manufacturing Metalyse

Petrovax presented the results of clinical trials for quadrivalent vaccine

NPO Petrovax Pharm presented the results of clinical trials for the first Russian-made quadrivalent vaccine

Construction of the second stage of Petrovax Pharm complex starts in Podolsk

A notice on the start of the construction of a pharmaceutical production and storage complex in Podolsk urban district was received by the Main Department of State Construction Supervision of the Moscow Region

NPO Petrovax Pharm will supply Grippol vaccine to Kazakhstan

NPO Petrovax Pharm began to export a flu-prevention vaccine to Kazakhstan

High safety profile of Russian drug confirmed in Europe

NPO Petrovax Pharm received a report on successful Post Authorization Safety Study (PASS) of Polyoxidonium® 6 mg injection in the European Union (Slovakia)

The launch of innovative thrombolytics onto the Russian market is expected in June

Boehringer Ingelheim and NPO Petrovax Pharm, a leading Russian manufacturer of immunobiological medicines, announced that the commercial series of innovative thrombolytics will be launched onto the Russian market as early as this June.

Petrovax launches the automation of drug registration business processes

Eureka BPO announced the launch of pilot operation of PHARDO system for LLC NPO Petrovax Pharm, a leading Russian developer and producer of innovative medicines and vaccines. The project allowed to au...

British-Russian consortium hopes to buy 25% of Serbia’s Galenika

A British-Russian consortium said they are close to an agreement for the purchase of 25% of Serbian majority state-owned drug maker Galenika, despite the government's recent announcement that the ...

IDF loan will enable Petrovax Pharm to increase production of substances and finished drugs

"The Advisory Committee of the Industrial Development Fund approved the first projects in 2017. Out of total 1.3 billion rubles for the implementation of the projects, 600 million rubles have to be co...

Petrovax Pharm is expanding production capacities

NPO Petrovax Pharm will increase the manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms (tablets and suppositories) of original local pharmaceuticals. It is planned to i...

Production of cardiovascular medications will be localized in Russia

NPO Petrovax Pharm and Boehringer Ingelheim continue their work to localise full-cycle production of biotechnological medicines to treat infarctions and cerebrovascular accidents. The project aiming ...